Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)
2015年8月27日 更新者:Vertex Pharmaceuticals Incorporated
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
The purpose of this study was to evaluate the safety and efficacy of ivacaftor in participants with cystic fibrosis (CF) who were aged 12 years or older and were homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation.
Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein.
Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic adenosine monophosphate (AMP)-dependent protein kinase A (PKA) activation.
研究概览
详细说明
This study investigated the effects of ivacaftor in participants with cystic fibrosis (CF) >=12 years of age with a forced expiratory volume in 1 second (FEV1) >=40 percent (%) predicted. This study was conducted in 2 parts.
- Part A of this study was a randomized, double-blind, placebo-controlled, parallel-group evaluation of participants with CF who were aged 12 years or older and were homozygous for the F508del-CFTR mutation.
- Part B of this study was an open-label extension of Part A, enrolling participants who completed Part A and met pre-specified endpoint criteria, and explored the safety and efficacy of ivacaftor over long-term treatment in participants with CF aged 12 years or older who were homozygous for the F508del-CFTR mutation.
研究类型
介入性
注册 (实际的)
140
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- University of Alabama
-
-
Alaska
-
Anchorage、Alaska、美国、99508
- Providence Medical Center
-
-
California
-
Oakland、California、美国、94611
- Kaiser Permanente Medical Care Program
-
-
Connecticut
-
Hartford、Connecticut、美国、06106
- Connecticut Children's Medical Center
-
-
Florida
-
Miami、Florida、美国、33136
- University of Miami Miller School of Medicine
-
Orlando、Florida、美国、32801
- Nemours Children's Clinic
-
-
Idaho
-
Boise、Idaho、美国、83712
- St. Luke's CF Clinic
-
-
Illinois
-
Chicago、Illinois、美国、60637
- University of Chicago
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Riley Hospital for Children
-
-
Maine
-
Portland、Maine、美国、04102
- Maine Medical Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital
-
Worcester、Massachusetts、美国、01655
- University of Massachussetts Medical School
-
-
Michigan
-
Grand Rapids、Michigan、美国、49503
- Helen DeVos Children's Hospital; Spectrum Health Hospitals
-
-
Missouri
-
Kansas City、Missouri、美国、64108
- The Children's Mercy Hospital
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Long Branch、New Jersey、美国、07740
- Monmouth Medical Center
-
Morristown、New Jersey、美国、07962
- Morristown Memorial Hospital
-
-
New York
-
Albany、New York、美国、12208
- Albany Medical College
-
Buffalo、New York、美国、14222
- Women and Children's Hospital of Buffalo
-
Hawthorne、New York、美国、10532
- New York Medical College
-
New York、New York、美国、10032
- Columbia University Medical Center
-
New York City、New York、美国、10003
- The CF Center, Beth Israel Medical Center
-
-
Ohio
-
Akron、Ohio、美国、44308
- Akron Children's Hospital
-
Cincinnati、Ohio、美国、45229
- Cincinnati Children's Hospital
-
Toledo、Ohio、美国、43606
- Toldedo Children's Hospital
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Hershey、Pennsylvania、美国、17033
- Hershey Medical Center
-
Philadelphia、Pennsylvania、美国、19134
- St. Christopher's Hospital for Children
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis、Tennessee、美国、38103
- University of Tennessee
-
-
Texas
-
Fort Worth、Texas、美国、76104
- Cook Children's Medical Center
-
-
Utah
-
Salt Lake City、Utah、美国、84132
- Univeristy of Utah
-
-
Vermont
-
Colchester、Vermont、美国、05446
- Vermont Lung Center at the University of Vermont
-
-
Virginia
-
Richmond、Virginia、美国、23298
- Medical College of Virginia
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
12年 及以上 (孩子、成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Confirmed diagnosis of cystic fibrosis (CF) and homozygous for F508del-CFTR mutation
- Forced expiratory volume in 1 second (FEV1) of at least 40% of predicted normal for age, gender, and height
- Willing to use at least 2 highly effective birth control methods during the study
- No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator
- Able to understand and comply with protocol requirements, restrictions, and instructions and likely to complete the study as planned, as judged by the investigator
Exclusion Criteria:
- History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject
- Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study
- History of alcohol, medication or illicit drug abuse within one year prior to Day 1
- Abnormal liver function >=3 x the upper limit of normal
- Abnormal renal function at Screening
- History of solid organ or hematological transplantation
- Pregnant or breast-feeding (for women)
- Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to screening
- Previous participation in a VX-809 study
- Used inhaled hypertonic saline treatment
- Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP3A4)
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
|
药片
Tablet
其他名称:
|
|
实验性的:Ivacaftor
Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
|
Tablet
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part A : Absolute Change From Part A Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 16
大体时间:Part A baseline through Week 16
|
Spirometry (as measured by ppFEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
ppFEV1 (predicted for age, gender, and height) was calculated using the Knudson method.
|
Part A baseline through Week 16
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Part A : Absolute Change From Part A Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 16
大体时间:Part A baseline through Week 16
|
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for participants with cystic fibrosis.
Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; Higher scores indicating fewer symptoms and better health-related quality of life.
|
Part A baseline through Week 16
|
|
Part A : Absolute Change From Part A Baseline in Sweat Chloride Concentration Through Week 16
大体时间:Part A baseline through Week 16
|
The sweat chloride (quantitative pilocarpine iontophoresis) test is a standard diagnostic tool for cystic fibrosis (CF), serving as an indicator of cystic fibrosis transmembrane conductance regulator (CFTR) activity.
|
Part A baseline through Week 16
|
|
Part A : Rate of Change From Baseline in Weight Through Week 16
大体时间:Part A baseline through Week 16
|
As malnutrition is common in participants with cystic fibrosis (CF) because of increased energy expenditures due to lung disease and fat malabsorption, body weight is an important clinical measure of nutritional status.
|
Part A baseline through Week 16
|
|
Part B : Absolute Change From Part A and Part B Baseline in ppFEV1 Through Week 64
大体时间:Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64
|
ppFEV1 is defined in Outcome Measure 1.
|
Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64
|
|
Part B : Rate of Change From Part A Baseline in ppFEV1 Through Week 64
大体时间:Part A baseline through Week 64
|
ppFEV1 is defined in Outcome Measure 1.
|
Part A baseline through Week 64
|
|
Part B : Rate of Change From Part B Baseline in ppFEV1 Through Week 64
大体时间:Part B baseline through Week 64
|
ppFEV1 is defined in Outcome Measure 1.
|
Part B baseline through Week 64
|
|
Part B : Absolute Change From Part A and Part B Baseline in CFQ-R Respiratory Domain Score Through Week 64
大体时间:Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64
|
The CFQ-R is a validated patient-reported outcome measuring health-related quality of life for participants with cystic fibrosis.
Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; Higher scores indicating fewer symptoms and better health-related quality of life.
|
Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64
|
|
Part B : Absolute Change From Part A and Part B Baseline in Sweat Chloride Concentration Through Week 64
大体时间:Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64
|
The sweat chloride (quantitative pilocarpine iontophoresis) test is a standard diagnostic tool for cystic fibrosis (CF), serving as an indicator of cystic fibrosis transmembrane conductance regulator (CFTR) activity.
|
Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64
|
|
Part B : Absolute Change From Part A and Part B Baseline in Weight Through Week 64
大体时间:Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64
|
As malnutrition is common in patients with cystic fibrosis (CF) because of increased energy expenditures due to lung disease and fat malabsorption, body weight is an important clinical measure of nutritional status.
|
Change from Part A baseline: Part A Baseline, Week 64; Change from Part B baseline: Part B Baseline (Week 16), Week 64
|
|
Part B : Number of Participants With Pulmonary Exacerbations
大体时间:Part B baseline through Week 64
|
Pulmonary exacerbation was defined as new, or changed, antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of the following signs/symptoms: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees Celsius; anorexia or weight loss; sinus pain or tenderness; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent (%); and radiographic changes indicative of pulmonary infection.
|
Part B baseline through Week 64
|
|
Part B : Number of Pulmonary Exacerbation Events
大体时间:Part B baseline through Week 64
|
Pulmonary exacerbation was defined as new, or changed, antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of the following signs/symptoms: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees Celsius; anorexia or weight loss; sinus pain or tenderness; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent (%); and radiographic changes indicative of pulmonary infection.
|
Part B baseline through Week 64
|
|
Part B : Number of Pulmonary Exacerbation Events Per Participant Per Year
大体时间:Part B baseline through Week 64
|
Pulmonary exacerbation was defined as new, or changed, antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of the following signs/symptoms: change in sputum; new or increased hemoptysis; increased cough; increased dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees Celsius; anorexia or weight loss; sinus pain or tenderness; change in sinus discharge; change in physical examination of the chest; decrease in pulmonary function by 10 percent (%); and radiographic changes indicative of pulmonary infection.
|
Part B baseline through Week 64
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Patrick A Flume, MD、Medical University of South Carolina
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2009年9月1日
初级完成 (实际的)
2010年7月1日
研究完成 (实际的)
2013年5月1日
研究注册日期
首次提交
2009年8月4日
首先提交符合 QC 标准的
2009年8月5日
首次发布 (估计)
2009年8月6日
研究记录更新
最后更新发布 (估计)
2015年9月11日
上次提交的符合 QC 标准的更新
2015年8月27日
最后验证
2015年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.